🧪
hypothesis

Vagus Nerve as Anatomical Highway for Prion-Like α-Syn Propagation

Hypothesis

Vagus Nerve as Anatomical Highway for Prion-Like α-Syn Propagation

Enteric α-synuclein misfolding spreads retrogradely via vagal afferents to DMV, then progressively to SNc (Braak stages III-VI).
🧬 SNCA/p-SNCA (Ser129)/GBA/LRRK2🩺 neurodegeneration🎯 Composite 44%💱 $0.53▼3.6%proposed
EvidencePending (0%)📖 0 cit🗣 3 debates✓ 12 support✗ 2 oppose
✓ All Quality Gates Passed
Mechanistic 0.65 (15%) Evidence 0.45 (15%) Novelty 0.35 (12%) Feasibility 0.30 (12%) Impact 0.50 (12%) Druggability 0.25 (10%) Safety 0.60 (8%) Competition 0.55 (6%) Data Avail. 0.55 (5%) Reproducible 0.50 (5%) KG Connect 0.50 (8%) 0.440 composite
🏆 ChallengeResolve: Vagus Nerve as Anatomical Highway for Prion-Like α-Syn Propagation$250 →
☰ Compare⚔️ Duel⚛️ Collide
📄 Export LaTeX
arXiv PreprintNeurIPSNature MethodsPLOS ONE
📖 Export BibTeXinteract with this hypothesis
Composite44% · Elo1500(0 matches)

🧪 Overview

Enteric α-synuclein misfolding spreads retrogradely via vagal afferents to DMV, then progressively to SNc (Braak stages III-VI). While anatomically compelling, the central assumption that enteric pathology is the initiating event is contested. Overexpression artifacts dominate animal models; vagotomy protection is inconsistently replicated. Best therapeutic strategy: transcutaneous vagus nerve stimulation (t-VNS) for desynchronization rather than blocking physical propagation.

🧬 Mechanism

🧬 Curated Mechanism Pathway

Curated pathway from expert analysis

flowchart TD
    A["SNCA Alpha-Synuclein<br/>Presynaptic Protein"]
    B["SNCA Misfolding<br/>Environmental Stress"]
    C["SNCA Oligomers<br/>Toxic Protofibrils"]
    D["Mitochondrial Pore<br/>Membrane Disruption"]
    E["Lewy Body Formation<br/>Cytoplasmic Inclusions"]
    F["Dopaminergic Neuron<br/>Dysfunction/Death"]
    G["Nigrostriatal Degeneration<br/>Motor Symptoms"]
    H["SNCA A53T/A30P/E46K<br/>Familial PD Mutations"]
    A --> B
    B --> C
    C --> D
    C --> E
    D --> F
    E --> F
    F --> G
    H -.->|"accelerates"| B
    style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
    style C fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
    style G fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
    style H fill:#7b1fa2,stroke:#ce93d8,color:#ce93d8

⚖️ Evidence

⚖️ Evidence Matrix6 supports2 contradicts
Supports
Movement of prion-like α-synuclein along the gut-brain axis in Parkinson's disease.
2021PMID:34043864
Supports
Intrastriatal injection of Parkinson's disease intestine and vagus lysates initiates pathology.
2024PMID:36604420
Supports
The Neural Gut-Brain Axis of Pathological Protein Aggregation in Parkinson's Disease.
2021PMID:34372600
Supports
Evidence for bidirectional and trans-synaptic parasympathetic and sympathetic propagation pathways.
2019PMID:31254094
Supports
The Gut-Brain Axis: Two Ways Signaling in Parkinson's Disease.
2021PMID:33649989
Supports
Accumulation of prion protein in the vagus nerve in Creutzfeldt-Jakob disease — comparative evidence for vagal highway.
2019PMID:30801763
Contradicts
Vagotomy studies show inconsistent results across populations — some show reduced PD risk after truncal vagotomy, others find no association.
Contradicts
Prion-like hypothesis for α-syn still contested — alternative mechanisms include shared genetic background, microbiome metabolites, and systemic inflammation.
📖 Linked Papers (6)Export BibTeX ↗
The Gut-Brain Axis Based on &#x3b1;-Synuclein Propagation-Clinical, Neuropathological, and Experimental Evidence.
International journal of molecular sciences (2025) · PubMed:40362234 ↗
3 figures
Figure 1
Figure 1
Lewy bodies (LBs) and a pale body. ( a ) An LB and ( b ) a pale body in a dopamine neuron in the substantia nigra. ( c ) An LB in the dorsal motor nucleus of th...
Figure 2
Figure 2
Prion-like propagation of aSyn pathology in PD. (Upper panel) Misfolded aSyn works as a seed, convert wild-type aSyn into an abnormal conformation, and amplify ...
Lewy Body Disease Primate Model with α-Synuclein Propagation from the Olfactory Bulb.
Mov Disord (2022) · PubMed:35989519 ↗
No figures
Movement of prion-like α-synuclein along the gut-brain axis in Parkinson's disease: A potential target of curcumin treatment.
The European journal of neuroscience (2021) · PubMed:34043864 ↗
No figures
Neural connectivity predicts spreading of alpha-synuclein pathology in fibril-injected mouse models: Involvement of retrograde and anterograde axonal propagation.
Neurobiol Dis (2020) · PubMed:31628991 ↗
No figures
Transneuronal Propagation of Pathologic α-Synuclein from the Gut to the Brain Models Parkinson's Disease.
Neuron (2019) · PubMed:31255487 ↗
No figures
Neuron-to-neuron α-synuclein propagation in vivo is independent of neuronal injury.
Acta Neuropathol Commun (2015) · PubMed:25853980 ↗
No figures

🏥 Translation

🧬 3D Protein Structure — SNCA

🧬 PDB 1XQ8 Click to expand

Experimental structure from RCSB PDB | Powered by Mol*

🧠 GTEx v10 Brain ExpressionJSON

Median TPM across 13 brain regions for SNCA/p-SNCA (Ser129)/GBA/LRRK2 from GTEx v10.

Cerebellar Hemisphere61.9 Frontal Cortex BA959.1 Anterior cingulate cortex BA2447.5 Cerebellum44.6 Cortex36.0 Spinal cord cervical c-125.7 Amygdala24.9 Nucleus accumbens basal ganglia21.6 Substantia nigra20.8 Hippocampus19.0 Hypothalamus18.5 Caudate basal ganglia13.5 Putamen basal ganglia12.4median TPM (GTEx v10)

💉 Clinical Trials (5)Relevance: 58%

0
Active
0
Completed
0
Total Enrolled
NA
Highest Phase
Aquaporin-4 Single Nucleotide Polymorphisms in Patients With Idiopathic and Familial Parkinson's DiseaseUnknown
ACTIVE_NOT_RECRUITING·NCT04553185 · University of Exeter
Parkinson Disease
Study procedure
Cohort Study to Identify Predictor Factors of Onset and Progression of Parkinson's DiseaseUnknown
RECRUITING·NCT02305147 · Institut National de la Santé Et de la Recherche Médicale, France
Parkinson Disease
Clinical, biological and imaging followup
Digitally-enhanced, Decentralized, Multi-omics Observational CohortUnknown
ENROLLING_BY_INVITATION·NCT04701177 · Greece 2021 Committee
Presymptomatic Disease Mild Cognitive Impairment Memory Loss (Excluding Dementia)
Teleph0s digital phenotyping platform
PPMI Clinical - Establishing a Deeply Phenotyped PD CohortUnknown
RECRUITING·NCT04477785 · Michael J. Fox Foundation for Parkinson's Research
Parkinson Disease
Establishing 18F PMPBB3 (APN 1607) PET Imaging Markers for Diagnosis of Tauopathy Parkinsonism SyndromesNA
COMPLETED·NCT04557865 · National Taiwan University Hospital
Tau Distributions in Patients With Tauopathy Using APN-1607 PET Scan
18F-PMPBB3 (APN-1607) PET imaging

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for SNCA →

No DepMap CRISPR Chronos data found for SNCA.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

🏆 Tournament

🏆 Arenas / Elo

Elo Rating
1500 ±350
Record
0W / 0L / 0D
0 matches
Full Lineage ➔

📊 Market Indicators

7d Trend
↔
Stable
7d Momentum
▼ 0.6%
Volatility
Medium
0.0483
Events (7d)
3
Price History
▼3.6%

💾 Resource Usage

API Calls
3
Total Cost
$0.0000

🔮 Predictions

🔎 Predictions vs Observations2 predictions · 0 with recorded observations
PredictionPredictedObservedStatusConf
IF enteric α-synuclein pathology (phosphorylated Ser129 aggregates) is experimentally seeded in the gastric wall of non-human primates followed by comprehensive neuropathological assessment at 18 montp-SNCA aggregates present in DMV with confirmed vagal axonal transport markers (NFL, phosphorylated neurofilament), quantified as ≥15 aggregates per DMV section— no observation —pending0.40
IF early-stage Parkinson's disease patients (Hoehn-Yahr stage 1-2) receive transcutaneous vagus nerve stimulation (t-VNS, 25 Hz, 30 min daily) for 12 months, THEN their longitudinal DAT-scan binding rDAT-scan binding ratio decline ≤15% in t-VNS group vs. ≥30% in sham group over 12 months, with corresponding slower MDS-UPDRS Part III progression— no observation —pending0.35
🔮 Falsifiable Predictions (2)
pendingconf 40%
IF enteric α-synuclein pathology (phosphorylated Ser129 aggregates) is experimentally seeded in the gastric wall of non-human primates followed by comprehensive neuropathological assessment at 18 months post-inoculation, THEN p-SNCA aggregates will be detectable in the dorsal motor nucleus of the va
Predicted outcome: p-SNCA aggregates present in DMV with confirmed vagal axonal transport markers (NFL, phosphorylated neurofilament), quantified as ≥15 aggregates per D
Falsification: If p-SNCA aggregates are absent in DMV despite verified gastric seeding (confirmed by immunohistochemistry and ELISA) in >50% of animals at 18 months, the retrograde vagal propagation hypothesis is fa
pendingconf 35%
IF early-stage Parkinson's disease patients (Hoehn-Yahr stage 1-2) receive transcutaneous vagus nerve stimulation (t-VNS, 25 Hz, 30 min daily) for 12 months, THEN their longitudinal DAT-scan binding ratios in the caudate/putamen will decline by ≤15% compared to sham controls, indicating slowed dopam
Predicted outcome: DAT-scan binding ratio decline ≤15% in t-VNS group vs. ≥30% in sham group over 12 months, with corresponding slower MDS-UPDRS Part III progression
Falsification: If t-VNS-treated patients show identical or greater dopaminergic degeneration (≥30% binding decline) and motor progression compared to sham controls, the desynchronization therapeutic hypothesis is fa
View on SciDEX ↗